Market Overview:
The global argininemia drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of argininemia, rising awareness about the disease, and technological advancements in the field of drug development. The global argininemia drugs market is segmented on the basis of type, application, and region. On the basis of type, it is divided into oral and injection segments. The oral segment dominates this market owing to its ease-of-use and lower cost as compared to injection therapies. By application, it is classified into hospital, drug stores, and other segments. The hospital segment accounts for a major share of this market due to increased diagnosis rates for argininemia patients in hospitals across the globe.
Product Definition:
Argininemia Drugs is a medication used to treat high levels of arginine in the blood. Arginine is an amino acid that can build up and cause health problems if it is not removed from the body by the kidneys. Argininemia Drugs helps remove arginine from the blood and prevents its buildup.
Oral:
Argininemia is a rare disease that affects one in every 100,000 people in the U.S. and less than 20,000 people globally. The disease is caused due to an abnormal growth factor (arginine) that builds up in the body and leads to vascular occlusion which ultimately causes death of brain tissue by restricting blood flow through the capillaries of brain tissues leading to stroke or hemorrhage (bleeding).
Injection:
Injection is the most common and easy way to deliver arginine in humans. It is a form of supplementation that can be taken orally but has very low bioavailability. The majority of injectable supplements are formulated with the combination of amino acids, caffeine, and taurine. Arginine itself has poor oral bioavailability due to its rapid degradation by intestinal enzymes; hence it is injected as a supplement to increase blood levels for effective results.
Application Insights:
Drug stores and hospitals are the major application segments of arginine-free drugs. The hospital segment dominated the global market in terms of revenue in 2017, owing to a high prevalence of cardiovascular diseases, cancer and respiratory disorders. Arginine-free drugs are used for various purposes such as treatment of acute coronary syndrome (ACS) or angina pectoris, prevention from cardiovascular diseases or heart attack through lifestyle modification and dietary changes, improvement in blood flow to the heart through use of nitroglycerine patches during cardiac arrest recovery period also known as percutaneous coronary intervention (PCI), reduction/prevention from mortality associated with sepsis by enhancing wound healing process through use oncology also known as antimicrobial activity enhancement therapy (AET).
The other segment is expected to be fastest growing application over the forecast period due to increasing R&D initiatives by pharmaceutical companies for introduction new drug molecules that can replace arginine-free formulations.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of patients suffering fromargininemia and increasing awareness about these disorders. The U.S., in particular, is estimated to hold a major share due to high healthcare expenditure and availability of effective treatment for rare diseases. Europe also held a considerable share due to high R&D investments by pharmaceutical companies for the development of novel drugs with improved therapeutic index as comparedto existing therapies.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure, growing patient awareness levels coupled with increased spending capacity among individuals belonging arginine-intolerant population groups especially in India & China which are amongstthe largest markets globally for generic drugs (approximately 60% - 70% generics sales).
Growth Factors:
- Increasing prevalence of argininemia due to genetic mutations
- Growing demand for novel therapeutics for the treatment of argininemia
- Rising awareness about argininemia and its treatment options
- increasing investment in research and development for new drugs to treat argininemia
- Availability of government funding and support to promote research on rare diseases such as argininemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Argininemia Drugs Market Research Report
By Type
Oral, Injection
By Application
Hospital, Drugs Stores, Other
By Companies
Helsinn Healthcare, Novartis Pharmaceuticals, Horizon Pharma, Medicis Pharmaceutical, Helsinn Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Argininemia Drugs Market Report Segments:
The global Argininemia Drugs market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Helsinn Healthcare
- Novartis Pharmaceuticals
- Horizon Pharma
- Medicis Pharmaceutical
- Helsinn Healthcare
Highlights of The Argininemia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Hospital
- Drugs Stores
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Argininemia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Argininemia drugs are medications that help to improve the function of the arginine-rich proteins in the body. These proteins play a role in many important processes, including blood clotting and nerve function. Argininemia drugs can be used to treat a variety of conditions, such as high blood pressure, heart disease, and stroke.
Some of the major players in the argininemia drugs market are Helsinn Healthcare, Novartis Pharmaceuticals, Horizo​​n Pharma, Medicis Pharmaceutical, Helsinn Healthcare.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Argininemia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Argininemia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Argininemia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Argininemia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Argininemia Drugs Market Size & Forecast, 2018-2028
4.5.1 Argininemia Drugs Market Size and Y-o-Y Growth
4.5.2 Argininemia Drugs Market Absolute $ Opportunity
Chapter 5 Global Argininemia Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Argininemia Drugs Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Argininemia Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Argininemia Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Stores
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Argininemia Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Argininemia Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Argininemia Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Argininemia Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Argininemia Drugs Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Argininemia Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Stores
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Argininemia Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Argininemia Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Argininemia Drugs Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Argininemia Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Stores
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Argininemia Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Argininemia Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Argininemia Drugs Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Argininemia Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Stores
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Argininemia Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Argininemia Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Argininemia Drugs Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Argininemia Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Stores
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Argininemia Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Argininemia Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Argininemia Drugs Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Argininemia Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Stores
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Argininemia Drugs Market: Competitive Dashboard
14.2 Global Argininemia Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Helsinn Healthcare
14.3.2 Novartis Pharmaceuticals
14.3.3 Horizon Pharma
14.3.4 Medicis Pharmaceutical
14.3.5 Helsinn Healthcare
